scholarly journals Mutational Landscape of Intermediate-Risk and Poor-Risk Acute Myeloid Leukemia (AML) Adult Patients by Next-Generation Sequencing (NGS): One Academic Center’s Experience

2018 ◽  
Vol 150 (suppl_1) ◽  
pp. S154-S154
Author(s):  
Betty Chung ◽  
Jessica Thomas ◽  
Randall Olsen
Keyword(s):  
Acute Myeloid Leukemia ◽  
Next Generation Sequencing ◽  
Myeloid Leukemia ◽  
Adult Patients ◽  
Intermediate Risk ◽  
Next Generation ◽  
Mutational Landscape ◽  
Next Generation Sequencing Ngs ◽  
Generation Sequencing ◽  
Acute Myeloid

Impact of next-generation sequencing (NGS) on treatment selection in acute myeloid leukemia (AML).

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 103-103
Author(s):  
Rita Elias Assi ◽  
Ana Alfonso Pierola ◽  
Devendra KC ◽  
Yasmin Mohammed Abaza ◽  
Abdallah Abou Zahr ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Next Generation Sequencing ◽  
Myeloid Leukemia ◽  
Treatment Selection ◽  
Next Generation ◽  
Next Generation Sequencing Ngs ◽  
Generation Sequencing ◽  
Acute Myeloid

scholarly journals Molecular Risk Stratification using Next-generation Sequencing in Acute Myeloid Leukemia

2021 ◽  
Vol 96 (6) ◽  
pp. 493-500
Author(s):  
Jae-Sook Ahn
Keyword(s):  
Acute Myeloid Leukemia ◽  
Next Generation Sequencing ◽  
Risk Stratification ◽  
Myeloid Leukemia ◽  
Chromosomal Abnormalities ◽  
Residual Disease ◽  
Next Generation ◽  
Next Generation Sequencing Ngs ◽  
Generation Sequencing ◽  
Acute Myeloid

Chromosomal abnormalities are an important prognostic factor in cases of acute myeloid leukemia (AML). Molecular mutations have been reported to contribute to the pathogenesis and prognosis of AML. Next-generation sequencing (NGS) has revolutionized the speed and cost of genomic sequencing and enables the parallel analysis of many genes for molecular risk stratification. The molecular mutations currently included in risk stratification at AML diagnosis are c-kit, FLT3-ITD, NPM1, CEBPA (biallelic), RUNX1, ASLX1, and TP53. The importance of screening for mutations has been further emphasized by introducing novel therapeutic targets for molecular mutations, such as FLT3-TKD, IDH1, and IDH2. Molecular mutations are also used to evaluate measurable residual disease during treatment and to select the intensity of the treatment during consolidation and follow-up. Pretreatment leukemic marrow and blood should be stored at a biobank to perform NGS analysis in cases of AML at diagnosis. Samples from various time points during and after treatment should be obtained and stored under appropriate conditions.

Sign in / Sign up

Export Citation Format

Share Document